fda safety communication semaglutide naion 2025 linked to increased risk of vision loss in diabetes patients Semaglutide use in patients with

In November of 2023 the approval of a combo GLP-1/GIP for weight loss indications was announced

Importantly, 32.5% of patients enrolled did not have T2DM and 14.5% had an eGFR below 30 mL/min/1.73 m 2 , demonstrating the benefit of dapagliflozin across a range of kidney function regardless of diabetes status [47]

However, more research should focus on the long-term effects of NR or other NAD + precursors in neurodegenerative patients

Who Should Stay on GLP-1 Compounds Long-Term: Safety and Clinical Considerations GLP-1 compounds are indicated for patients with obesity or overweight with comorbidities

Patients should be monitored for signs of dehydration, especially during dose titration, and should maintain adequate fluid intake unless otherwise directed by their healthcare provider